| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Feb, 2026 |
| Sales | 30 | 30 | 410 | 1,530 | 0 |
| Sales Growth | unch | -92.68% | -73.20% | unch | unch |
| Net Income | -24,850 | -13,360 | -5,670 | -2,050 | 0 |
| Net Income Growth | -86.00% | -135.63% | -176.59% | unch | unch |
Carbylan Therap Cmn (CBYL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Carbylan Therapeutics, Inc. is a specialty pharmaceutical company which focused on the development and commercialization of combination therapies that address unmet medical needs. The Company's product candidate consists of Hydros-TA, which is in clinical trial to treat pain associated with osteoarthritis of the knee. Carbylan Therapeutics, Inc. is headquartered in Palo Alto, California.